Egyptian International Pharmaceutical Industries Co 2022 AR2

The report highlights EIPICO's performance for the fiscal year ended December 31, 2022. The company achieved record production exceeding EGP 4 billion, representing a 16.6% growth, and maintained its leading position in the Egyptian pharmaceutical market. EIPICO expanded its global footprint to 74 countries, with export sales reaching USD 52.6 million. Key strategic developments included progress on the EIPICO 3 factory for biologicals and biosimilars, and the launch of the EIPICO Pharma 4.0 digital transformation project. Additionally, the company aligned its operations with 12 UN Sustainable Development Goals and maintained a 6% employment rate for persons with disabilities.

Company: Egyptian International Pharmaceutical Industries Co

Sector: Health Care

Country: Egypt

Year: 2022

Type: AR2

Pages: 143

Back to company

Egyptian International Pharmaceutical Industries Co

Egyptian International Pharmaceutical Industries Co 2022 Annual Report

Annual Report

The report highlights EIPICO's performance for the fiscal year ended December 31, 2022. The company achieved record production exceeding EGP 4 billion, representing a 16.6% growth, and maintained its leading position in the Egyptian pharmaceutical market. EIPICO expanded its global footprint to 74 countries, with export sales reaching USD 52.6 million. Key strategic developments included progress on the EIPICO 3 factory for biologicals and biosimilars, and the launch of the EIPICO Pharma 4.0 digital transformation project. Additionally, the company aligned its operations with 12 UN Sustainable Development Goals and maintained a 6% employment rate for persons with disabilities.

Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.

Document Details

Report Year

2022

Reporting Period

Jan 1, 2022 - Dec 31, 2022

Fiscal Year

2022

Type

Annual Report with Sustainability Disclosures

Language

English, Arabic

Pages

 

File Size

 

Standards & Assurance

Materiality Assessment

Assurance

Assurance Provider

Assurance Standard

ESG Data?Experimental — AI-extracted data, may contain inaccuracies

Employees